Trial Profile

MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Jun 2024 Results (n=116, data cut-off: 02 Nov 2023) assessing the study endpoints at final analysis evaluating DOR per BICR, PFS per BICR, OS, and safety, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
09 Nov 2023 Status changed from active, no longer recruiting to completed.
24 Oct 2023 Results of exploratory analysis assessing the impact of concomitant baseline genomic alterations on the clinical activity of tucatinib plus trastuzumab, presented at the 48th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com